New hope for kidney patients: diabetes drugs tested to fight nephrotic syndrome
NCT ID NCT07214818
First seen Oct 31, 2025 · Last updated Jun 11, 2026 · Updated 28 times
Summary
This study tests whether two diabetes drugs (dapagliflozin and empagliflozin) can help adults with nephrotic syndrome, a kidney condition that causes protein leakage and swelling. About 75 participants will receive either one of these drugs plus standard care, or standard care alone, for 6 months. The goal is to see if these drugs reduce protein in urine, maintain remission, and prevent relapse, while monitoring kidney function and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEPHROTIC SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Urology & Nephrology Center, Mansoura University
RECRUITINGAl Mansurah, Dakahlia Governorate, 35516, Egypt
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.